六月 2026
- Home
- Cellipont Bioservices
六月 2026的Cellipont Bioservices市场份额分析
Milpitas, CA and The Woodlands, TX — March 24, 2026 / Cision / – Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced
Cellipont Bioservices(包含公司地区分支机构)
查看更多网站流量和参与度信息- cellipont.com
Cellipont Bioservices收入截至 六月 2026为 2M - 5M
Cellipont Bioservices主要域名产生的收入
3 年中Cellipont Bioservices主要域名的收入
Cellipont Bioservices主要域名的收入
Cellipont Bioservices热门域名的总访问量
了解Cellipont Bioservices市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Cellipont Bioservices热门域名的平均访问时长
分析Cellipont Bioservices参与度指标。
过去 3 个月的平均访问时长
子公司明细
Cellipont Bioservices热门域名的平均页面浏览量
了解Cellipont Bioservices如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Cellipont Bioservices 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Applied StemCell, Inc. partners with Cellipont Bioservices.Applied StemCell and Cellipont Bioservices partner to offer a seamless path for iPSC-derived cell therapy development.
三月 24, 2026阅读更多
新闻Cellipont Bioservices partnered with BobcatBio on Mar 17th '26.The WOODLANDS, Texas and HUMMELSTOWN, Pa - March 16, 2026/ Cision / - Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient's macrophages to elicit a robust, targeted tumoricidal immune response while substantially reducing or eliminating the reliance on traditional cancer treatments such as chemotherapy, high-dose radiation and surgery, thereby improving patient outcomes and quality of life.
三月 17, 2026阅读更多
查看 Cellipont Bioservices 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
